imatinib mesylate has been researched along with Dementias, Transmissible in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguib, Y; Baier, M; Ertmer, A; Gilch, S; Heiseke, A; Riemer, C; Schätzl, HM | 1 |
| Ertmer, A; Flechsig, E; Gilch, S; Klebl, B; Klein, MA; Schätzl, HM; Stein-Gerlach, M; Yun, SW | 1 |
2 other study(ies) available for imatinib mesylate and Dementias, Transmissible
| Article | Year |
|---|---|
Autophagy induction by trehalose counteracts cellular prion infection.
Topics: Animals; Autophagy; Benzamides; Cell Line; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Mice; Neurodegenerative Diseases; Neurons; Piperazines; Prion Diseases; Prions; Pyrimidines; RNA, Small Interfering; Time Factors; Trehalose | 2009 |
The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Imatinib Mesylate; Lysosomes; Mice; Piperazines; Prion Diseases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; PrPSc Proteins; Pyrimidines; Signal Transduction | 2004 |